Integra Biosciences Corp.

Integra Biosciences Corp., a foreign-owned manufacturer of advanced laboratory equipment headquartered in Hudson, New Hampshire, supplies specialized liquid handling systems, automated pipetting platforms, and laboratory instrumentation to federal biomedical research and regulatory agencies as a prime contractor on a portfolio of over 80 purchase orders and delivery orders across health, environmental, and agricultural agencies. The company competes predominantly on full-and-open and small business set-aside designations, with no characteristic SBA certifications; recent awards carry mixed set-aside postures — some designated as Total Small Business (on NAICS 334516, Analytical Laboratory Instrument Manufacturing), others unrestricted.

Integra's capability portfolio centers on proprietary liquid handling and pipetting systems — the VIAFLO 96/384 series, ASSIST PLUS robotic platforms, MINI 96 portable pipettes, and specialized media preparation equipment (MediaClaves, MediaJets, WellJet dispensers) — sold alongside preventative maintenance, calibration, and system-support services. Representative prime work includes a $23.6 thousand Total Small Business service agreement with the National Institute of Environmental Health Sciences for VIAFLO 96/384 maintenance (awarded February 2026, completion January 2027); an $18.9 thousand unrestricted preventative maintenance order from the EPA Office of Research and Development for VIAFLO 96/384 equipment (awarded December 2025); a $162.1 thousand delivery to the Fish and Wildlife Service for VIAFLO pipetting products and systems (July 2024); and a $55.6 thousand sale of an ASSIST PLUS Liquid Handling System to CDC Pittsburgh (September 2023). Recent COVID-19 work included pipetting systems procured by NIAID for multiplex immunoassay research.

Customer concentration sits heavily with the Department of Health and Human Services and affiliated civilian research agencies. The top five funding entities — NIH Office of the Director (55 awards, $309 thousand combined potential value), NIAID (39 awards, $1 million), CDC Pittsburgh (36 awards, $933 thousand), FDA (31 awards, $880 thousand), and NIEHS (18 awards, $415 thousand) — represent 53% of award volume but only 9% of combined potential value, reflecting Integra's business model of frequent, modest-dollar purchase orders rather than large task orders. Integra places 77 delivery orders under the GSA Multiple Award Schedule, the dominant parent vehicle, generating $2.2 million in combined potential value. The company has served fifty distinct federal agencies across HHS, EPA, USDA (Agricultural Research Service, Veterinary Services, Animal and Plant Health Inspection Service), DOI Fish and Wildlife Service, NOAA, and DoD (via the Defense Health Agency).

Award activity has declined measurably. Integra received 29 awards in 2022, 18 in 2023, 11 in 2024, and only 6 in 2025, tracking a year-over-year contraction that has extended into 2026 (one award through July). The company's total federal footprint spans 338 awards since 2008 with combined potential value of $38.2 million, of which $7.3 million (19%) has been obligated. Only two awards face ultimate completion within the next twenty-four months, representing $43 thousand in potential recompete exposure — minimal near-term recompete risk but also a signal of a narrowing, aging portfolio. Integra operates as a prime on 99.7% of its awards; a single sub-award appears in the portfolio (a WellJet Dispenser purchase modification under an unnamed prime, dated November 2024). NAICS concentration is acute: 224 of 338 awards fall under Analytical Laboratory Instrument Manufacturing (NAICS 334516), and 288 awards are classified under PSC Laboratory Equipment and Supplies, reflecting a monolithic product-line posture with minimal diversification into adjacent service categories.

Provider of high-quality laboratory tools for liquid handling, media preparation, sterilization and cell cultivation.